FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL								
	OMB Number:	3235-028							
1	F-4:	la considerati							

Check this box if no longer subject	t
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(h)	

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OIVID AFFROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Name and Address of Reporting Person* To all Marketin Territoria. To all Marketin Territoria. The second s					2. Issuer Name and Ticker or Trading Symbol Aquestive Therapeutics, Inc. [AQST]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Kendall Keith J					122	Agai j									X Dire		tor	10%	Owner	
(Last) (First) (Middle)					3. D	Date of Earliest Transaction (Month/Day/Year)								\dashv	X	Office below	er (give title v)	Othe belov	r (specify v)	
C/O AQUESTIVE THERAPEUTICS, INC.						12/31/2019									CEO and President					
30 TECHNOLOGY DRIVE																				
						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable					
(Street)				01/	01/02/2020										Line) X Form filed by One Reporting Person					
WARREI	WARREN NJ 07059													Form filed by More than One Reporting						
(City) (State) (Zip)														Person						
(City)	(5)																			
		Tabl	e I - Nor	1-Deriv	ative	Se	curitie	s Ac	quired,	Dis	posed o	f, or	Ben	efici	ally (Owne	ed			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da						Execution Da		n Date,	Code (Instr.						4 and Second Ben Owr		cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	((A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Common Stock 12/31/2					1/2019						149(1) D		\$5.	.82 670		70,811	D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date curity or Exercise (Month/Day/Year) if any		Date,	4. Transaction Code (Instr. 8)		of Of Derive Secue Acque (A) of Disposor (D)	Expiration (Month/II (Mont		e Exercisable and ation Date h/Day/Year) Expiration Date Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amour or Numbe of Title Shares		ount nber	ı		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		

Explanation of Responses:

1. This amendment is being filed solely to amend the number of withheld shares due to a mistake in the number of shares withheld upon vesting of RSUs as reported in the original Form 4 filed on January 2, 2020.

Remarks:

/s/ Robert Arnold, as Attorney- 02/25/2020 In-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.